结核病化疗药物吡嗪酰胺致高尿酸血症的危险因素研究

蒲强红; 李佳萌; 李凡敏; 袁术生

doi:10.16766/j.cnki.issn.1674-4152.002236

结核病化疗药物吡嗪酰胺致高尿酸血症的危险因素研究

doi: 10.16766/j.cnki.issn.1674-4152.002236

1.
乐山市人民医院药学部，四川乐山 614000
2.
乐山市人民医院感染性疾病科，四川乐山 614000
3.
乐山市人民医院呼吸内科，四川乐山 614000

基金项目:

四川省卫生和计划生育委员会科研课题 17PJ560

乐山市科技局重点研究项目 17SZD185

详细信息

通讯作者:
袁术生, E-mail: 1633883991@qq.com

中图分类号: R52 R978.3
计量
- 文章访问数: 275
- HTML全文浏览量: 192
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2021-02-04

Risk factors for tuberculosis chemotherapeutic drug pyrazinamide-induced hyperuricemia

1.
Department of Pharmacy, People's Hospital of Leshan, Leshan, Sichuan 614000, China

摘要

摘要: 目的评估结核病化疗药吡嗪酰胺致高尿酸血症的可能危险因素。方法纳入2016年7月—2020年12月期间乐山市人民医院感染性疾病科与呼吸内科确诊结核病的患者共98例，化疗强化期使用HRZE四联方案，根据强化期血尿酸水平分为高尿酸血症组(81例)与正常血尿酸组(17例)，收集年龄、性别、体重指数、吸烟史、饮酒史与慢性疾病史(糖尿病、高血压或冠心病)等资料，测定尿酸转运体URAT1与GLUT9基因多态性。结果高尿酸血症组与正常血尿酸组患者年龄、性别(男/女：50/31 vs. 8/9)、体重指数、吸烟史、饮酒史、慢性疾病史(糖尿病、高血压或冠心病：7/74 vs. 3/14)等指标比较差异无统计学意义(均P>0.05)。高尿酸血症组与正常血尿酸组肝肾功能生化指标ALT、白蛋白、总胆红素与血肌酐水平[(55.1±10.9)μmol/L vs. (58.2±12.6)μmol/L]差异无统计学意义(均P>0.05)。高尿酸血症组与正常血尿酸组URAT1基因多态性rs7932775(T1309C)、rs475688、rs3825016(C258T)的基因型比较差异无统计学意义(均P>0.05)，2组间GLUT9基因多态性rs3733591(R265H)、rs1014290的基因型差异亦无统计学意义(均P>0.05)。结论年龄、性别、体重指数、吸烟史、饮酒史、慢性疾病史(糖尿病、高血压或冠心病)、肝肾功能与URAT1、GLUT9基因多态性似乎不是结核病化疗药吡嗪酰胺致高尿酸血症的危险因素。
- 吡嗪酰胺 /
- 结核病 /
- 高尿酸血症 /
- 危险因素 /
- 基因多态性
Abstract: Objective To evaluate the possible risk factors for hyperuricemia induced by tuberculosis chemotherapeutic drug pyrazinamide. Methods Patients who were diagnosed with tuberculosis in the Department of Infection and Department of Respiratory in our hospital from July 2016 to December 2020 were enrolled. The isoniazid, rifampicin, pyrazinamide and ethambutol regimen were administrated daily in intensive period. Data of age, gender, body mass index, smoking history, drinking history and chronic disease history (diabetes, hypertension or coronary heart disease) were collected. The polymorphism of uric acid transporter URAT1 and GLUT9 gene were determined. Results No differences in age, sex(male/female: 50/31 vs. 8/9), BMI, smoking history, drinking history and chronic diseases (diabetes, hypertension or coronary heartdisease: 7/74 vs. 3/14) were found between two groups. There was no significant difference in ALT, albumin, total bilirubin and serum creatinine [(55.1±10.9)μmol/L vs. (58.2±12.6)μmol/L] in the two groups. There was no significant difference in the genotypes of URAT1 gene polymorphisms [rs7932775 (t1309c), rs475688, rs3825016 (c258t)] and GLUT9 gene polymorphisms [rs3733591 (r265h), rs1014290] between two groups (all P>0.05). Conclusion Age, sex, BMI, smoking history, drinking history, chronic diseases, hepatic and renal function, polymorphisms of URAT1 and GLUT9 gene might not be the risk factors for pyrazinamide-induced hyperuricemia.
- Pyrazinamide /
- Tuberculosis /
- Hyperuricemia /
- Risk factors /
- Gene polymorphism
利益冲突 无

HTML全文

表 1 2组结核病患者流行病学资料比较

组别	例数	性别(男/女, 例)	年龄[M(P₂₅, P₇₅)，岁]	BMI[M(P₂₅, P₇₅)]	饮酒(例)	吸烟(例)	有慢性疾病(例)
正常血尿酸组	17	8/9	48.0(25.5, 56.0)	20.1(18.0, 24.9)	4	7	3
高尿酸血症组	81	50/31	37.0(26.0, 53.0)	20.3(18.7, 22.1)	10	31	7
统计量		1.252^a	602.500^b	675.500^b	0.667^a	0.050^a	0.445^a
P值		0.263	0.424	0.906	0.414	0.823	0.500
注：^a为χ²值，^b为U值。

下载: 导出CSV

表 2 2组结核病患者肝肾功能生化指标比较

组别	例数	ALT[M(P₂₅, P₇₅)，U/L]	白蛋白(x±s，g/L)	总胆红素[M(P₂₅, P₇₅)，μmol/L]	血肌酐(x±s，μmol/L)
正常血尿酸组	17	24.0(17.0, 39.5)	33.2±6.9	8.3(5.2, 15.2)	55.1±10.9
高尿酸血症组	81	20.0(13.5, 33.0)	34.8±5.5	8.4(6.0, 10.7)	58.2±12.6
统计量		572.000^a	1.001^b	674.000^a	0.958^b
P值		0.278	0.320	0.895	0.340
注：^a为U值，^b为t值。

下载: 导出CSV

表 3 2组结核病患者URAT1基因多态性比较(例)

组别	例数	rs7932775(T1309C)			rs3825016(C258T)			rs475688
组别	例数	TT	TC	CC	CC	CT	TT	CC	CT	TT
正常血尿酸组	17	7	8	2	10	6	1	3	12	2
高尿酸血症组	81	19	46	16	49	29	3	27	41	13
χ²值		2.393			0.171			2.334
P值		0.302			0.918			0.311

下载: 导出CSV

表 4 2组结核病患者GLUT9多态性比较(例)

组别	例数	rs3733591(R265H)			rs1014290
组别	例数	CC	CT	TT	AA	AG	GG
正常血尿酸组	17	2	9	6	6	7	4
高尿酸血症组	81	13	35	33	36	34	11
χ²值		0.570			1.185
P值		0.752			0.553

下载: 导出CSV

参考文献(21)

[1]	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 肺结核基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2019, 18(8): 709-717. doi: 10.3760/cma.j.issn.1671-7368.2019.08.002
[2]	TURNBULL L, BELL C, CHILD F. Tuberculosis (NICE clinical guideline 33)[J]. Arch Dis Child Educ Pract Ed, 2017, 102(3): 136-42. doi: 10.1136/archdischild-2016-310870
[3]	MANDOVRA N P, LELE T T, VAIDYA P J, et al. High incidence of new-onset joint pain in patients on fluoroquinolones as antituberculous treatment[J]. Respiration, 2020, 99(2): 125-131. doi: 10.1159/000505102
[4]	李卉, 张宏亮, 杨天燕, 等. 我院125例抗结核药物不良反应报告分析[J]. 中国医药导报, 2020, 17(29): 151-154. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202029039.htm
[5]	韩冰, 胡柳杨, 姚亚超, 等. 合并糖尿病的结核病患者接受吡嗪酰胺治疗后高尿酸血症、痛风性关节炎发病情况观察[J]. 山东医药, 2020, 60(3): 60-62. doi: 10.3969/j.issn.1002-266X.2020.03.016
[6]	杨玫. 吡嗪酰胺对肺结核合并糖尿病患者高尿酸血症发生率及严重程度的影响分析[J]. 中国医药指南, 2019, 17(19): 2-3. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK201919002.htm
[7]	肖建华. 探讨吡嗪酰胺致严重高尿酸血症的影响因素及对抗结核治疗的影响[J]. 国际感染病学(电子版), 2019, 8(1): 120. https://www.cnki.com.cn/Article/CJFDTOTAL-GJGR201901096.htm
[8]	金玲玲, 施伎蝉, 蒋贤高, 等. 短程化疗方案在初次复发涂阳肺结核中的效果评价[J]. 中华全科医学, 2019, 17(9): 1508-1511. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201909021.htm
[9]	刘占中, 王春颖, 王亮, 等. 吡嗪酰胺不同给药频次的效果及药效学评价[J]. 河北医药, 2020, 42(19): 2981-2983, 2986. doi: 10.3969/j.issn.1002-7386.2020.19.025
[10]	韩珂卿, 余林红, 崔嘉佳, 等. 202例患者应用吡嗪酰胺后的不良反应分析[J]. 临床医学研究与实践, 2019, 4(14): 116-117. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS201914046.htm
[11]	刘硕, 康万里, 许瑞, 等. 吡嗪酰胺相关高尿酸血症患者血尿酸升高程度的影响因素分析[J]. 药物不良反应杂志, 2020, 22(12): 665-669. doi: 10.3760/cma.j.cn114015-20191225-01067
[12]	李媛媛, 苏东栋, 哈米提·努力克. 吡嗪酰胺引起糖尿病合并肺结核患者高尿酸血症的临床观察[J]. 当代医学, 2017, 23(20): 91-92. doi: 10.3969/j.issn.1009-4393.2017.20.045
[13]	陈智慧. 吡嗪酰胺对肺结核合并糖尿病患者高尿酸血症发生率及严重程度的影响[J]. 中国医药指南, 2017, 15(34): 131-132. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK201734105.htm
[14]	胡艳, 陶敏, 潘星, 等. 慢性肾脏病人群中高尿酸血症的患病率及危险因素研究[J]. 中华全科医学, 2020, 18(12): 1989-1993. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202012004.htm
[15]	ANDRADE SIERRA J, FLORES FONSECA M M. Renal handling of uric acid[J]. Contrib Nephrol, 2018, 192: 1-7.
[16]	TU H P, MIN-SHAN KO A, LEE S S, et al. Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout[J]. J Hum Genet, 2018, 63(1): 63-70. doi: 10.1038/s10038-017-0368-9
[17]	DUONG N T, NGOC N T, THANG N T M, et al. Polymorphisms of ABCG2 and SLC22A12 genes associated with gout risk in vietnamese population[J]. Medicina (Kaunas), 2019, 55(1): 8. doi: 10.3390/medicina55010008
[18]	ZOU Y, DU J, ZHU Y, et al. Associations between the SLC22A12 gene and gout susceptibility: A meta-analysis[J]. Clin Exp Rheumatol, 2018, 36(3): 442-447.
[19]	WAN ROHANI W T, MAHFUDZAH A, NAZIHAH M Y, et al. Association of solute carrier family 2, member 9 (SLC2A9) genetic variant rs3733591 with gout in a Malay sample set[J]. Med J Malaysia, 2018, 73(5): 307-310.
[20]	BEN SALEM C, SLIM R, FATHALLAH N, et al. Drug-induced hyperuricaemia and gout[J]. Rheumatology (Oxford), 2017, 56(5): 679-688.
[21]	ICHIDA K, HOSOYAMADA M, KAMATANI N, et al. Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese[J]. Clin Genet, 2008, 74(3): 243-251. doi: 10.1111/j.1399-0004.2008.01021.x